• 1
    Petropoulou AD, Rocha V: Risk factors and options to improve engraftment in unrelated cord blood transplantation. Stem Cells Int 2011; 2011:610514
  • 2
    Afessa B, Peters SG: Major complications following hematopoietic stem cell transplantation. Semin Respir Crit Care Med 2006; 27:297309
  • 3
    Crawford SW: Respiratory disease in bone marrow and hematopoietic stem cell transplantation; in Elias JA, Fishman JA, Grippi MA, et al. (eds): Fishman’s Pulmonary Disease and Disorders. New York, McGraw-Hill, 1998: 2137
  • 4
    Junghanss C, Marr KA, Carter RA, et al. : Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogenic hematopoietic stem cell transplantation: a matched control study. Biol Blood Marrow Transplant 2002; 8:512520
  • 5
    Junghanss C, Marr KA: Infectious risks and outcomes after stem cell transplantation: are nonmyeloablative transplants changing the picture? Curr Opin Infect Dis 2002; 15:347353
  • 6
    Zver S, Zadnik V, Cernelc P, et al. : Cardiac toxicity of high-dose cyclophosphamide and melphalan in patients with multiple myeloma treated with tandem autologous hematopoietic stem cell transplantation. Int J Hematol 2008; 88:227236
  • 7
    Rabinstein AA, Dispenzieri A, Micallef IN, et al. : Acute neuropathies after peripheral blood stem cell and bone marrow transplantation. Muscle Nerve 2003; 28:733736
  • 8
    Deeg HJ, Amylon ID, Harris RE, et al. : Marrow transplants from unrelated donors for patients with aplastic anemia: minimum effective dose of total body irradiation. Biol Blood Marrow Transplant 2001; 7:208215
  • 9
    Sullivan K, Storb R: Bone marrow transplantation and graft-versus-host disease; in Brend L, Sells R (eds): Bailliere’s Clinical Immunology and Allergy. London, Bailliere Tindall, 1989: 91
  • 10
    Hahn T, McCarthy PL Jr, Zhang MJ, et al. : Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia. J Clin Oncol 2008; 26:57285734
  • 11
    Brunstein CG, Barker JN, Weisdorf DJ, et al. : Umbilical cord blood transplantation after nonmyeloablative conditioning impact on transplantation outcomes in 110 adultswith hematologic disease. Blood 2007; 110:30643070
  • 12
    Pavletic S, Vogelsand GB: Treatment of high-risk chronic GVHD. Biol Blood Marrow Transplant 2008; 14:14361437
  • 13
    Arora M, Nagaraj S, Witte J, et al. : New classification of chronic GVHD: added clarity from the consensus diagnoses. Bone Marrow Transplant 2009; 43:149153
  • 14
    Socié G: Chronic GVHD: a new risk score? Blood 2011; 117:64086409
  • 15
    Arora M, Klein JP, Weisdorf DJ, et al. : Chronic GVHD risk score: a center for international blood and marrow transplant research analysis. Blood 2011; 117:67146720
  • 16
    Zaucha JM, Gooley T, Bensinger WI, et al. : CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral bloodmononuclear cell grafts affects engraftment kinetics and development of extensive chronicgraft-versus-host disease after human leukocyte antigen-identical sibling transplantation. Blood 2001; 98:32213227
  • 17
    Mohty M, Bilger K, Jourdan E, et al. : Higher doses of CD34 + peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation. Leukemia 2003; 17:869875
  • 18
    Mielcarek M, Martin PJ, Heimfeld S, et al. : CD34 cell dose and chronic graft-versus-host disease after human leukocyte antigen-matched sibling hematopoietic stem cell transplantation. Leuk Lymphoma 2004; 45:2734
  • 19
    Horwitz ME, Sullivan KM: Chronic graft-versus-host disease. Blood Rev 2006; 20:1527
  • 20
    Hildebrandt GC, Fazekas T, Lawitschka A, et al. : Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD. Bone Marrow Transplant 2011. March 28. [Epub ahead of print]
  • 21
    Page KM, Mendizabal AM, Prasad VK, et al. : Posttransplant autoimmune hemolytic anemia and other autoimmune cytopenias are increased in very young infants undergoing unrelated donor umbilical cord blood transplantation. Biol Blood Marrow Transplant 2008; 14:11081117
  • 22
    Bernardo ME, Pagliara D, Locatelli F: Mesenchymal stromal cell therapy: a revolution in Regenerative Medicine? Bone Marrow Transplant 2011. Apr 11. [Epub ahead of print]
  • 23
    Tolar J, Villeneuve P, Keating A: Mesenchymal stromal cells for graft-versus-host disease. Hum Gene Ther 2011; 22:257262
  • 24
    Toubai T, Paczesny S, Shono Y, et al. : Mesenchymal stem cells for treatment and prevention of graft-versus-host disease after allogeneic hematopoietic cell transplantation. Curr Stem Cell Res Ther 2009; 4:252259
  • 25
    Mielcarek M, Storb R, Georges GE, et al. : Mesenchymal stromal cells fail to prevent acute graft-versus-host disease and graft rejection after dog leukocyte antigen-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant 2011; 17:214225
  • 26
    Rubbia-Brandt L: Sinusoidal obstruction syndrome. Clin Liver Dis 2010; 14:651668
  • 27
    Richardson PG, Murakami C, Jin Z, et al. : Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood 2002; 100:43374343
  • 28
    Koenecke C, Kleine M, Schrem H, et al. : Sinusoidal obstruction syndrome of the liver after hematopoietic stem cell transplantation: decision making for orthotopic liver transplantation. Int J Hematol 2006; 83:271274
  • 29
    Sucak GT, Aki ZS, Yagcí M, et al. : Treatment of sinusoidal obstruction syndrome with defibrotide: a single-center experience. Transplant Proc 2007; 39:15581563
  • 30
    Dvorak CC, Wright NB, Wong WB, et al. : Safety of hematopoietic stem cell transplantation in children less than three years of age. Pediatr Hematol Oncol 2008; 25:705722